Poster Title
P-11 Novel Heterocyclic Arylidene Derivatives as Anticancer Agents against U87 Human Glioblastoma Cells
Abstract
The primary objective of this research study was to investigate the efficacy of novel hybrid heterocyclic arylidenes as anticancer agents against the proliferation and invasiveness of glioblastoma cancer cells. A group of novel heterocyclic arylidenes were produced from a set of aryl aldehydes and rhodanine acetic acid in a pancreatin-catalyzed controlled reflux reaction. These compounds were subsequently administered to U87 glioblastoma cancer cells at different concentrations in a 12-well cell viability assay to determine each compound’s LC50. Compounds showed various levels of efficacy and were dependent upon the substituent composition.
Start Date
2-28-2020 2:30 PM
P-11 Novel Heterocyclic Arylidene Derivatives as Anticancer Agents against U87 Human Glioblastoma Cells
The primary objective of this research study was to investigate the efficacy of novel hybrid heterocyclic arylidenes as anticancer agents against the proliferation and invasiveness of glioblastoma cancer cells. A group of novel heterocyclic arylidenes were produced from a set of aryl aldehydes and rhodanine acetic acid in a pancreatin-catalyzed controlled reflux reaction. These compounds were subsequently administered to U87 glioblastoma cancer cells at different concentrations in a 12-well cell viability assay to determine each compound’s LC50. Compounds showed various levels of efficacy and were dependent upon the substituent composition.
Acknowledgments
J.N. Andrews Honors Scholar
Mentors:
Denise Smith, Biology
Desmond H. Murray, Chemistry & Biochemistry